DISCLOSURE OF LARGE SHAREHOLDING | Gentian Diagnostics AS
medical, diagnostics, immunoassays, assays, in vitro diagnostics, IVD products, avian antibodies, antibodies, clinical chemistry, diagnostic tests, biotechnology
16349
post-template-default,single,single-post,postid-16349,single-format-standard,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-14.2,qode-theme-bridge,wpb-js-composer js-comp-ver-6.0.5,vc_responsive
 

Gentian Diagnostics AS – Disclosure of large shareholding

Gentian Diagnostics AS – Disclosure of large shareholding

(Oslo, 15 June 2018) Reference is made to the stock exchange notice published by Gentian Diagnostics AS (“Gentian”) earlier today regarding an investment in Gentian by Vatne Equity AS and Norron AB.

Vatne Equity AS will in connection with the investment be allocated 699,814 shares in Gentian in a private placement. Vatne Equity has today also acquired 50,000 shares in Gentian Diagnostics AS at a price of NOK 50 per share. Following the issuance of new shares in connection with the private placement and the share purchase, Vatne Equity AS will hold 1,599,814 shares in Gentian, corresponding to 10.39%% of the outstanding shares.

In addition, Lioness AS, a sister company of Vatne Equity AS, owns 150,000 shares in Gentian, corresponding to 1.07% of the outstanding shares.

Following the issuance of new shares in connection with the private placement and the share purchase, Vatne Equity AS and Lioness AS will together hold 1,749,814 shares in Gentian, corresponding to 11.37% of the outstanding shares.

 

For further information, please contact:

Henrik Krefting, CEO
(+47) 916 12 279 / Email: hk@vatnecapital.com

 

MeldingsID: 453766
UtstederID: GENT-ME
Instrument: GENT-ME
Marked: Merkur Market
Kategori: FLAGGING
Informasjonspliktige opplysninger: Ja
Vedlegg: 2018 06 15 Flaggemelding -Vatne Equity AS (1)